Biodesix (NASDAQ:BDSX) and Concentra Group Holdings Parent (NYSE:CON) Critical Contrast

Concentra Group Holdings Parent (NYSE:CON) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Concentra Group Holdings Parent and Biodesix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concentra Group Holdings Parent	0	2	3	0	2.60
Biodesix	1	0	5	0	2.67

Concentra Group Holdings Parent presently has a consensus target price of $30.00, indicating a potential upside of 41.84%. Biodesix has a consensus target price of $32.50, indicating a potential upside of 128.71%. Given Biodesix’s stronger consensus rating and higher possible upside, analysts plainly believe Biodesix is more favorable than Concentra Group Holdings Parent.

Risk and Volatility

Concentra Group Holdings Parent has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Institutional & Insider Ownership

21.0% of Biodesix shares are held by institutional investors. 6.6% of Concentra Group Holdings Parent shares are held by company insiders. Comparatively, 30.1% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Concentra Group Holdings Parent and Biodesix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Concentra Group Holdings Parent	7.69%	48.46%	6.24%
Biodesix	-39.85%	-1,760.83%	-40.28%

Valuation & Earnings

This table compares Concentra Group Holdings Parent and Biodesix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concentra Group Holdings Parent	$2.16 billion	1.26	$166.41 million	$1.30	16.27
Biodesix	$88.50 million	1.58	-$35.26 million	($4.85)	-2.93

Concentra Group Holdings Parent has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Concentra Group Holdings Parent, indicating that it is currently the more affordable of the two stocks.

Summary

Concentra Group Holdings Parent beats Biodesix on 8 of the 14 factors compared between the two stocks.

About Concentra Group Holdings Parent

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.